- Independent in relation to the Company and its management: No
- Independent in relation to major shareholders: Yes
- Holdings in Alligator: 83,720 shares, 250,000 warrants in program TO 2022/2025 I, and 600,000 warrants in program TO 2023/2026 I.
- Other current positions: None
Peter Ellmark – born 1973, Chief Scientific Officer – holds a PhD and an associate professorship in Immunotechnology at Lund University. Peter has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Employed since 2008 and member of the Management Team since 2018.